Research Keyword: mucormycosis treatment

Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing

mycolabadmin

A patient with a serious fungal infection of the sinuses caused by Rhizopus arrhizus received the antifungal drug isavuconazole. However, blood tests showed the drug was building up to dangerously high levels in her body. Genetic testing revealed she had a mutation that made her body unable to break down the drug normally. The doctors had to give her much smaller and less frequent doses while carefully monitoring her drug levels to keep her safe.

Read More »

Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018–2023)

mycolabadmin

This research examined dangerous mold infections (Mucormycosis) that became more common after COVID-19. Scientists identified the types of molds causing these infections in Iran by testing 116 patient samples and 65 soil samples from across the country. They tested these molds against 13 different antifungal medications to find which drugs work best. The results showed that amphotericin B and posaconazole were the most effective medications, and patient samples were more susceptible to these drugs than environmental soil samples.

Read More »

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

mycolabadmin

Scientists developed a new way to test antifungal drugs using silkworms instead of expensive and ethically problematic mammal studies. They infected silkworms with mucormycosis-causing fungi and found that the infections behaved similarly to human cases, especially when they simulated human risk factors like steroid use and iron overload. The silkworm model successfully demonstrated that existing antifungal drugs work, while also revealing differences in fungal virulence that were linked to specific surface proteins.

Read More »
Scroll to Top